BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37549750)

  • 1. The Surveillance for Presumed BD-IPMN of the Pancreas.
    Deng H; Dou W; Pan Y
    Gastroenterology; 2024 May; 166(5):939-940. PubMed ID: 37549750
    [No Abstract]   [Full Text] [Related]  

  • 2. Can the location of the mural nodule indicate benign or malignant in branch duct-type intraductal papillary mucinous neoplasm of the pancreas?
    Niiya F; Ohike N; Norose T; Takano Y; Azami T; Kobayashi T; Maruoka N; Wakabayashi T; Matsuo K; Tanaka K; Nagahama M
    Pancreatology; 2020 Oct; 20(7):1379-1385. PubMed ID: 32873485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer history: A predictor of IPMN subtype and dysplastic status?
    Carr RA; Kiel BA; Roch AM; Ceppa EP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    Am J Surg; 2018 Mar; 215(3):522-525. PubMed ID: 29174163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between hyperechogenic pancreas and pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasms.
    Mandai K; Uno K; Nakase K; Kawamura T; Yasuda K
    J Med Ultrason (2001); 2019 Oct; 46(4):435-439. PubMed ID: 31069577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic ductal adenocarcinomas associated with intraductal papillary mucinous neoplasms (IPMNs) versus pseudo-IPMNs: relative frequency, clinicopathologic characteristics and differential diagnosis.
    Muraki T; Jang KT; Reid MD; Pehlivanoglu B; Memis B; Basturk O; Mittal P; Kooby D; Maithel SK; Sarmiento JM; Christians K; Tsai S; Evans D; Adsay V
    Mod Pathol; 2022 Jan; 35(1):96-105. PubMed ID: 34518632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Management of Pancreatic Premalignant Lesions.
    Søreide K; Marchegiani G
    Gastroenterology; 2022 Feb; 162(2):379-384. PubMed ID: 34678216
    [No Abstract]   [Full Text] [Related]  

  • 7. Surveillance for Presumed BD-IPMN of the Pancreas: Stability, Size, and Age Identify Targets for Discontinuation.
    Marchegiani G; Pollini T; Burelli A; Han Y; Jung HS; Kwon W; Rocha Castellanos DM; Crippa S; Belfiori G; Arcidiacono PG; Capurso G; Apadula L; Zaccari P; Noia JL; Gorris M; Busch O; Ponweera A; Mann K; Demir IE; Phillip V; Ahmad N; Hackert T; Heckler M; Lennon AM; Afghani E; Vallicella D; Dall'Olio T; Nepi A; Vollmer CM; Friess H; Ghaneh P; Besselink M; Falconi M; Bassi C; Goh BK; Jang JY; Fernández-Del Castillo C; Salvia R
    Gastroenterology; 2023 Oct; 165(4):1016-1024.e5. PubMed ID: 37406887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digital PCR-based plasma cell-free DNA mutation analysis for early-stage pancreatic tumor diagnosis and surveillance.
    Okada T; Mizukami Y; Ono Y; Sato H; Hayashi A; Kawabata H; Koizumi K; Masuda S; Teshima S; Takahashi K; Katanuma A; Omori Y; Iwano H; Yamada M; Yokochi T; Asahara S; Kawakubo K; Kuwatani M; Sakamoto N; Enomoto K; Goto T; Sasajima J; Fujiya M; Ueda J; Matsumoto S; Taniue K; Sugitani A; Karasaki H; Okumura T
    J Gastroenterol; 2020 Dec; 55(12):1183-1193. PubMed ID: 32939577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of patients with branch-duct intraductal papillary mucinous neoplasm and very low risk of cancer: multicentre study.
    Tamburrino D; de Pretis N; Pérez-Cuadrado-Robles E; Uribarri-Gonzalez L; Ateeb Z; Belfiori G; Maisonneuve P; Capurso G; Vanella G; Petrone MC; Arcidiacono PG; Vaalavuo Y; Frulloni L; Dominguez-Muñoz JE; Deprez PH; Falconi M; Del Chiaro M; Crippa S; Laukkarinen J
    Br J Surg; 2022 Jun; 109(7):617-622. PubMed ID: 35511697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intraductal papillary mucinous neoplasm of pancreas].
    Panteleev VI; Gorin DS; Kaldarov AR; Kriger AG
    Khirurgiia (Mosk); 2019; (11):81-87. PubMed ID: 31714535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Landmark Series: Intraductal Papillary Mucinous Neoplasms of the Pancreas-From Prevalence to Early Cancer Detection.
    Pollini T; Wong P; Maker AV
    Ann Surg Oncol; 2023 Mar; 30(3):1453-1462. PubMed ID: 36600097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic CT density is an optimal imaging biomarker for earlier detection of malignancy in the pancreas with intraductal papillary mucinous neoplasm.
    Yamada D; Kobayashi S; Takahashi H; Yoshioka T; Iwagami Y; Tomimaru Y; Shigekawa M; Akita H; Noda T; Asaoka T; Gotoh K; Tanemura M; Doki Y; Eguchi H
    Pancreatology; 2022 May; 22(4):488-496. PubMed ID: 35396159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal Surveillance Interval of Branch Duct Intraductal Papillary Mucinous Neoplasm of the Pancreas.
    Han Y; Kwon W; Lee M; Jung HS; Yun WG; Cho YJ; Chae YS; Fernández-Del Castillo C; Marchegiani G; Salvia R; Goh BKP; Lee WJ; Jang JY
    JAMA Surg; 2024 Apr; 159(4):389-396. PubMed ID: 38231494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of Deep Learning Analysis for the Diagnosis of Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Kuwahara T; Hara K; Mizuno N; Okuno N; Matsumoto S; Obata M; Kurita Y; Koda H; Toriyama K; Onishi S; Ishihara M; Tanaka T; Tajika M; Niwa Y
    Clin Transl Gastroenterol; 2019 May; 10(5):1-8. PubMed ID: 31117111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular Vesicle Analysis Allows for Identification of Invasive IPMN.
    Yang KS; Ciprani D; O'Shea A; Liss AS; Yang R; Fletcher-Mercaldo S; Mino-Kenudson M; Fernández-Del Castillo C; Weissleder R
    Gastroenterology; 2021 Mar; 160(4):1345-1358.e11. PubMed ID: 33301777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An integrated analysis of host- and tumor-derived markers for predicting high-grade dysplasia and associated invasive carcinoma of intraductal papillary mucinous neoplasms of the pancreas.
    Hata T; Mizuma M; Motoi F; Ishida M; Morikawa T; Nakagawa K; Hayashi H; Kanno A; Masamune A; Kamei T; Naitoh T; Furukawa T; Unno M
    Surg Today; 2020 Sep; 50(9):1039-1048. PubMed ID: 32124086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of invasive carcinoma in branch type intraductal papillary mucinous neoplasms of the pancreas.
    Kanno A; Satoh K; Hirota M; Hamada S; Umino J; Itoh H; Masamune A; Asakura T; Shimosegawa T
    J Gastroenterol; 2010 Sep; 45(9):952-9. PubMed ID: 20383536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnostics and treatment of intraductal papillary mucinous pancreas neoplasm].
    Khatkov IE; Poroshina EG; Solovyeva OI; Tokareva TP; Vorobyev SL; Bakulina NV
    Ter Arkh; 2023 Oct; 95(8):686-691. PubMed ID: 38158906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical assessment of the GNAS mutation status in patients with intraductal papillary mucinous neoplasm of the pancreas.
    Ohtsuka T; Tomosugi T; Kimura R; Nakamura S; Miyasaka Y; Nakata K; Mori Y; Morita M; Torata N; Shindo K; Ohuchida K; Nakamura M
    Surg Today; 2019 Nov; 49(11):887-893. PubMed ID: 30879148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cystic pancreatic lesions-indications, timing and reasons for surveillance].
    Vornhülz M; Sirtl S; Orgler E; Weniger M; Schirra J; Beyer G; Mayerle J
    Radiologie (Heidelb); 2023 Dec; 63(12):900-907. PubMed ID: 37878017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.